AstraZeneca is buying Fusion Pharmaceuticals, a Canadian company specializing in radioconjugation cancer treatments, for $2.4 billion.
Petru Nicolaescu
Health
Unsplash.com
Always see our news on Google
The acquisition of Fusion Pharmaceuticals by AstraZeneca brings innovative new treatments to the company's portfolio. Radioconjugates developed by Fusion are an alternative to chemotherapy and radiotherapy, minimizing damage to healthy cells. The most advanced treatment, FPI-2265, is for patients with metastatic prostate cancer.
Latest News
22:57
AI companies and chipmakers lose more than $1 trillion amid concerns over financing
22:46
Salvamont rescuers are warning drivers and tourists after snow began falling on the Transfăgărășan and in Poiana Brașov
22:39
The Niculescu Government proposes exempting mothers from paying CASS and maintaining the child-rearing allowance after returning to work
22:25
Niculescu Government targets a deficit below 3% of GDP by 2030 / Spending, tax evasion and revenue collection are priorities
21:55
The government proposed by Luca Niculescu wants to attract a strategic investor to TAROM in 2027, including for a majority stake
See more news
NEWS ON THE SAME TOPICS
International
AstraZeneca, negotiations with Bristol Myers Squibb for a possible merger that could create a 400 billion dollar group
IT&C knowledge
Novo collaborates with Anthropic to use artificial intelligence in the research and development of new medicines
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
